TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Medicines Advice Service: A Randomised Controlled Trial of a Pharmacy-based Telephone Intervention to Support Patients Taking Medication for a Long-term Condition
Brief Summary: The purpose of this study is to find out whether talking to a pharmacist on the telephone can help to support people taking medicine for a long-term condition.


Options:
A: Arm Label: Pharmaceutical care; Type: EXPERIMENTAL; Interventions: Other: Pharmaceutical care | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmaceutical care; Assigned to Arm(s): Pharmaceutical care
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pharmacist obtains home med hx; Type: EXPERIMENTAL; Interventions: Other: Pharmacist obtains admission medication history | Arm Label: Pharm tech obtains home med hx; Type: EXPERIMENTAL; Interventions: Other: Pharmacy technician obtains admission medication history | Intervention Type: OTHER; Name: Pharmacist obtains admission medication history; Assigned to Arm(s): Pharmacist obtains home med hx | Intervention Type: OTHER; Name: Pharmacy technician obtains admission medication history; Assigned to Arm(s): Pharm tech obtains home med hx
C: Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Complex tailored intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Complex tailored intervention | Intervention Type: BEHAVIORAL; Name: Complex tailored intervention; Assigned to Arm(s): Complex tailored intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: Patient-centred tailored intervention; Type: EXPERIMENTAL; Interventions: Other: Medicines Advice Service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Medicines Advice Service; Assigned to Arm(s): Patient-centred tailored intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Remote Ischaemic Preconditioning and Glyceryl Trinitrate on Peri-operative Myocardial Injury in Cardiac Bypass Surgery Patients (ERIC-GTN Study)
Brief Summary: The purpose of this study is to determine whether Glyceryl Trinitrate (GTN) reduces injury to the heart during heart-lung bypass surgery in combination with the newer technique of remote ischaemic preconditioning (RIPC).


Options:
A: Arm Label: Group 1 Control (65 patients); Type: SHAM_COMPARATOR; Interventions: Drug: IV Normal saline | Arm Label: Group 2 (65 patients); Type: ACTIVE_COMPARATOR; Interventions: Other: Remote ischaemic preconditioning, Drug: IV Normal saline | Arm Label: Group 3 GTN (65 patients):; Type: EXPERIMENTAL; Interventions: Drug: IV Glyceryl trinitrate 2-5ml/h | Arm Label: • Group 4 RIPC+GTN (65 patients):; Type: EXPERIMENTAL; Interventions: Other: Remote ischaemic preconditioning, Drug: IV Glyceryl trinitrate 2-5ml/h | Intervention Type: OTHER; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Group 2 (65 patients), • Group 4 RIPC+GTN (65 patients): | Intervention Type: DRUG; Name: IV Normal saline; Assigned to Arm(s): Group 1 Control (65 patients), Group 2 (65 patients) | Intervention Type: DRUG; Name: IV Glyceryl trinitrate 2-5ml/h; Assigned to Arm(s): Group 3 GTN (65 patients):, • Group 4 RIPC+GTN (65 patients):
B: Arm Label: Remote preconditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischemic preconditioning | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning; Assigned to Arm(s): Remote preconditioning | Intervention Type: PROCEDURE; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: SHAM_COMPARATOR; Interventions: Procedure: Control/sham procedure (blood pressure cuff) | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control/sham procedure (blood pressure cuff); Assigned to Arm(s): CONTROL
D: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control | Arm Label: Remote ischaemic conditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischaemic preconditioning | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic conditioning | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Abdomen: Vacuum Pack Versus Sylo Bag and Mesh Protocol - A Randomized Trial
Brief Summary: The open abdomen is a valid and accepted surgical tactic for the trauma and acute care patient. There have been many mechanisms described for its management, but the most accepted strategy is the vacuum pack. At our hospital the investigators have used for many years a double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation. At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. Every day the investigators try to tighten the mesh with sutures until the abdomen can be closed. This study´s objective is to compare our double sylo bag- mesh protocol with the vacuum pack to determine which is related to a higher fascial closure rate.


Options:
A: Arm Label: Open Abdomen Management with ANPPT dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Open Abdomen Management with ANPPT dressing | Arm Label: Closed Abdomen Management; Type: SHAM_COMPARATOR; Interventions: Other: Closed Abdomen Management | Intervention Type: DEVICE; Name: Open Abdomen Management with ANPPT dressing; Assigned to Arm(s): Open Abdomen Management with ANPPT dressing | Intervention Type: OTHER; Name: Closed Abdomen Management; Assigned to Arm(s): Closed Abdomen Management
B: Arm Label: Open Abdomen patients; Type: N/A; Interventions: Procedure: Open abdomen procedure | Intervention Type: PROCEDURE; Name: Open abdomen procedure; Assigned to Arm(s): Open Abdomen patients
C: Arm Label: "Stampede" VAC; Type: ACTIVE_COMPARATOR; Interventions: Device: "Stampede" VAC | Arm Label: KCI AbThera; Type: EXPERIMENTAL; Interventions: Device: KCI AbThera | Intervention Type: DEVICE; Name: KCI AbThera; Assigned to Arm(s): KCI AbThera | Intervention Type: DEVICE; Name: "Stampede" VAC; Assigned to Arm(s): "Stampede" VAC
D: Arm Label: Open Abdomen - Vacuum Pack; Type: EXPERIMENTAL; Interventions: Device: Vacuum Pack | Arm Label: Double Sylo Bag - Mesh Protocol; Type: ACTIVE_COMPARATOR; Interventions: Device: Double Sylo Bag - Mesh Protocol | Intervention Type: DEVICE; Name: Vacuum Pack; Assigned to Arm(s): Open Abdomen - Vacuum Pack | Intervention Type: DEVICE; Name: Double Sylo Bag - Mesh Protocol; Assigned to Arm(s): Double Sylo Bag - Mesh Protocol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Post-abortion Care and Contraceptive Counselling by Midwives or Physicians - a Randomized Controlled Trial in Kisumu, Western Kenya
Brief Summary: The aim of this project is to study the safety, efficacy and effectiveness of medical treatment of incomplete abortion provided to women by physicians or midwives in Kisumu, Kenya.

In Kenya, Post Abortion Care (PAC), provided by physicians, nurse-midwives and clinical officers, has been integrated at private reproductive health facilities since 1998. Misoprostol as treatment of incomplete abortion was launched I Nyanza Province in April, 2012. The involvement of midwives in medical (Misoprostol) treatment of incomplete abortion has, however, not been systematically evaluated. There is a need to determine whether midwives and physician can perform medical treatment of incomplete abortion equally safe and effective in Kenya. The results will thus provide evidence-based information that can contribute to the development of strategies to increase women's access to Post Abortion Care in Kenya as well as in other low-income contexts.


Options:
A: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
B: Arm Label: Medical Post Abortion Care by Midwife; Type: OTHER; Interventions: Other: Medical Post Abortion Care | Arm Label: Medical Post Abortion Care by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Medical Post Abortion Care; Assigned to Arm(s): Medical Post Abortion Care by Midwife
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): B
D: Arm Label: misoprostol by midwife; Type: OTHER; Interventions: Other: misoprostol by midwife | Arm Label: Misoprostol by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: misoprostol by midwife; Assigned to Arm(s): misoprostol by midwife

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Naltrexone for Antipsychotic-Induced Weight Gain
Brief Summary: This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications. Naltrexone is an FDA approved medication for the management of alcohol dependence and drug dependence, but has not been fully evaluated for its effect on weight loss in individuals with severe mental illness (i.e. schizophrenia, schizoaffective disorder, bipolar disorder etc.) The purpose of this study is to find out how effective two different doses of oral naltrexone is on reducing body weight when compared to placebo (an inactive substance or "sugar pill").


Options:
A: Arm Label: Naltrexone 50mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Naltrexone 25mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone 25mg, Naltrexone 50mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: quetiapine fumarate; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine versus risperidone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine versus risperidone | Intervention Type: DRUG; Name: olanzapine versus risperidone; Assigned to Arm(s): 1, 2
D: Arm Label: Olanzapine/standard behavioral weight intervention; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine, Behavioral: Standard behavioral weight intervention | Arm Label: Olanzapine/intense behavioral weight intervention; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine, Behavioral: Intense behavioral weight intervention | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine/intense behavioral weight intervention, Olanzapine/standard behavioral weight intervention | Intervention Type: BEHAVIORAL; Name: Standard behavioral weight intervention; Assigned to Arm(s): Olanzapine/standard behavioral weight intervention | Intervention Type: BEHAVIORAL; Name: Intense behavioral weight intervention; Assigned to Arm(s): Olanzapine/intense behavioral weight intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage
Brief Summary: Null hypothesis: 10 IU Oxytocin is better than sublingual misoprostol 600µg in management of third stage of labor Alternative hypothesis: Sublingual misoprostol 600µg is non- inferior to 10 IU oxytocin and will not be more than 6% worse \[than 10 IU oxytocin\] in management of third stage of labor


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, PLACEBO
B: Arm Label: Syntocinon; Type: ACTIVE_COMPARATOR; Interventions: Drug: Syntocinon | Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Syntocinon; Assigned to Arm(s): Syntocinon | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol
C: Arm Label: Arm A: sublingual misoprostol 600µg; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Arm B: 10 IU Oxytocin; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Arm A: sublingual misoprostol 600µg
D: Arm Label: TXA; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): TXA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage
Brief Summary: Null hypothesis: 10 IU Oxytocin is better than sublingual misoprostol 600µg in management of third stage of labor Alternative hypothesis: Sublingual misoprostol 600µg is non- inferior to 10 IU oxytocin and will not be more than 6% worse \[than 10 IU oxytocin\] in management of third stage of labor


Options:
A: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Carbetocin; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
B: Arm Label: Syntocinon; Type: ACTIVE_COMPARATOR; Interventions: Drug: Syntocinon | Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Syntocinon; Assigned to Arm(s): Syntocinon | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol
C: Arm Label: Arm A: sublingual misoprostol 600µg; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Arm B: 10 IU Oxytocin; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Arm A: sublingual misoprostol 600µg
D: Arm Label: Carbetocin 80mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 90mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 110mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 120mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 80mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 90mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 100mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 110mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 120mcg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients With Advanced Melanoma
Brief Summary: This study will evaluate the safety and efficacy of 2 different dosing schedules of pembrolizumab (MK-3475), every 2 weeks (Q2W) and every 3 weeks (Q3W), and compare the 2 schedules to treatment with ipilimumab in ipilimumab-naïve participants with unresectable or metastatic melanoma. The primary hypotheses are that pembrolizumab is superior to ipilimumab with respect to progression-free survival (PFS) and overall survival (OS).


Options:
A: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Placebo + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Placebo | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab, Placebo + Ipilimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Ipilimumab
B: Arm Label: CETUXIMAB AND DASATINIB; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: Dasatinib | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): CETUXIMAB AND DASATINIB | Intervention Type: DRUG; Name: Dasatinib; Assigned to Arm(s): CETUXIMAB AND DASATINIB
C: Arm Label: Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab | Arm Label: Pembrolizumab Q2W; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab Q3W; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab Q2W, Pembrolizumab Q3W | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab
D: Arm Label: postop chemoradio with cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Radiation: chemoradiotherapy with cisplatin | Arm Label: postop chemoradio (cisplatin)+gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Iressa (Gefitinib) | Intervention Type: DRUG; Name: Iressa (Gefitinib); Assigned to Arm(s): postop chemoradio (cisplatin)+gefitinib | Intervention Type: RADIATION; Name: chemoradiotherapy with cisplatin; Assigned to Arm(s): postop chemoradio with cisplatin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients With Advanced Melanoma
Brief Summary: This study will evaluate the safety and efficacy of 2 different dosing schedules of pembrolizumab (MK-3475), every 2 weeks (Q2W) and every 3 weeks (Q3W), and compare the 2 schedules to treatment with ipilimumab in ipilimumab-naïve participants with unresectable or metastatic melanoma. The primary hypotheses are that pembrolizumab is superior to ipilimumab with respect to progression-free survival (PFS) and overall survival (OS).


Options:
A: Arm Label: GSK2118436; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Arm Label: Dacarbazine (DTIC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine (DTIC) | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Crossover, GSK2118436 | Intervention Type: DRUG; Name: Dacarbazine (DTIC); Assigned to Arm(s): Dacarbazine (DTIC)
B: Arm Label: Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab | Arm Label: Pembrolizumab Q2W; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab Q3W; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab Q2W, Pembrolizumab Q3W | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab
C: Arm Label: Sequential D + T, THEN Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Concurrent D + T AND Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Pembrolizumab ONLY; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Pembrolizumab ONLY, Sequential D + T, THEN Pembrolizumab
D: Arm Label: Ipilimumab 10 mg/kg + HDI; Type: EXPERIMENTAL; Interventions: Drug: administration of ipilimumab10mg/kg | Arm Label: Ipilimumab 3mg/kg + HDI; Type: EXPERIMENTAL; Interventions: Drug: administration of ipilimumab 3mg/kg + HDI | Intervention Type: DRUG; Name: administration of ipilimumab10mg/kg; Assigned to Arm(s): Ipilimumab 10 mg/kg + HDI | Intervention Type: DRUG; Name: administration of ipilimumab 3mg/kg + HDI; Assigned to Arm(s): Ipilimumab 3mg/kg + HDI

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vascular Inflammation in Psoriasis - Extension Study
Brief Summary: VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid metabolism, and inflammatory markers. VIP-E extends VIP study procedures for 40-52 weeks including questionnaires, physical exams, blood and urine samples, lab tests, one additional FDG-PET/CT scan, and adalimumab injections following FDA-approved psoriasis treatment regimen.


Options:
A: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg | Arm Label: Placebo then Secukinumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: DRUG; Name: Secukinumab 300 mg; Assigned to Arm(s): Secukinumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo then Secukinumab
B: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
C: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial
D: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A

Answer: C